Bupropion and Naltrexone Obesity Drug
Links shared publicly online about this topic
Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave (Naltrexone SR/Bupropion SR)
medicalnewstoday.com — “Contrave (naltrexone SR/bupropion SR), an investigational drug aimed at combination therapy to address both biological and behavioral drivers of obesity, will be developed and commercialized by Or” View full resource at medicalnewstoday.com
Most Recently Shared on September 2, 2010 at 7:23 pm By:
Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave (Naltrexone SR/Bupropion SR) http://mnt.to/3Jfz #healthnews
COR-I: naltrexone/bupropion combo as obesity drug | theheart.org
theheart.org — “New randomized trial results suggest the combination of two” View full resource at theheart.org
Most Recently Shared on July 29, 2010 at 10:36 pm By:
COR-I: Combo drug leads to significant weight loss, but CV effects questioned: New randomized trial results sugges... http://bit.ly/bMzyaY
Combination Naltrexone And Bupropion For Obesity Leads To Substantial Reductions In Bodyweight
medicalnewstoday.com — “Combination treatment for obesity using the drugs naltrexone and bupropion, plus diet and exercise, helps reduce bodyweight by a mean of 5% or more over a year, depending on the dosage used. The f” View full resource at medicalnewstoday.com
Most Recently Shared on August 3, 2010 at 11:43 am By:
Sara Stein MD Doctor, Psychiatrist, and Physician
#obesity - Good study on naltrexone & bupropion (with diet & exercise) for weight reduction - a good combination;... http://fb.me/t9suo6ZR
Effect of naltrexone plus bupropion on weight loss... [Lancet. 2010] - PubMed result
ncbi.nlm.nih.gov — “PubMed is a service of the U.S. National Library of Medicine that includes over 19 million citations from MEDLINE and other life science journals for biomedical articles back to the 1950s. PubMed includes links to full text articles and other related resources.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on August 30, 2010 at 2:18 pm By:
Zack (Sholem) Berger Physician, Doctor, and Internist
Moderately effective medical therapy for #obesity in good-quality trial: bupropion + naltrexone. http://bit.ly/9wSqCT
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial : The Lancet
thelancet.com — “Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. By - Prof Frank L Greenway MD,...” View full resource at thelancet.com
Most Recently Shared on August 22, 2010 at 1:41 am By:
Symposier Endocrino Health Site
Combination Weight Loss Drugs Appear Effective for Obesity. http://bit.ly/cjn0cN
COR trials: Combination bupropion, naltrexone improved cardiometabolic risk markers
endocrinetoday.com — “The Obesity Society’s 27th Annual Scientific Meeting New data from the COR program demonstrate significant improvement in markers of car” View full resource at endocrinetoday.com
Most Recently Shared on October 29, 2009 at 5:47 pm By:
#Obesity2009 COR trials: Combination bupropion, naltrexone improved cardiometabolic risk markers http://ow.ly/xmjF
Obesity Drug, Contrave Gets Green Light From FDA Advisory Panel
medicalnewstoday.com — “Experimental drug Contrave(R) (naltrexone SR/bupropion SR) for the treatment of obesity has been recommended for approval by the FDA's Endocrinologic and Metabolic Drugs Advisory Committee. The Co” View full resource at medicalnewstoday.com
Most Recently Shared on December 8, 2010 at 6:01 pm By:
Obesity Drug, Contrave Gets Green Light From FDA Advisory Panel Experimental drug Contrave(R) (naltrexone SR/bupropion .. http://dld.bz/9Ufx
Medical News: FDA Says No to Weight-Loss Combo Drug - in Primary Care, Obesity from MedPage Today
medpagetoday.com — “A pill combining bupropion and naltrexone for weight loss (Contrave) won't receive the FDA's approval until its manufacturer, Orexigen, conducts a new clinical trial evaluating its cardiovascular risk” View full resource at medpagetoday.com
Most Recently Shared on February 1, 2011 at 5:39 pm By:
Evelyn Tribole Nutritionist, Dietitian, and Active Health Library
FDA Says No to Weight-Loss Combo Drug, Contrave, which consists of bupropion and naltrexone. http://bit.ly/g6SOkp
FDA Issues Complete Response to New Drug Application for Contrave for the Management of Obesity
drugs.com — “Contrave (bupropion SR/naltrexone SR) is a new drug combination in development for the treatment of obesity. Contrave information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on February 9, 2011 at 12:13 am By:
Drugs and Devices OW OW Health
FDA Issues Complete Response to New Drug Application for Contrave for the Management of Obesity: SAN DIEGO... http://bit.ly/i8PT1E #drug
Orexigen Therapeutics' Investigational Drug Contrave Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
drugs.com — “Contrave (bupropion SR/naltrexone SR) is a new drug combination in development for the treatment of obesity. Contrave information includes news, clinical trial results and side effects.” View full resource at drugs.com
Most Recently Shared on December 9, 2010 at 11:05 pm By:
Drugs and Devices OW OW Health
Orexigen Therapeutics' Investigational Drug Contrave Receives Positive Recommendation from FDA Advisory Co... http://bit.ly/i7jynQ #drug
Medical News: OBESITY: CVD Risk Cut With Rejected Weight-Loss Drug - in Meeting Coverage, OBESITY from MedPage Today
medpagetoday.com — “ORLANDO -- It appears that the investigational weight-loss combination of naltrexone standard release and bupropion standard release (Contrave) reduces the predicted 10-year risk of cardiovascular eve” View full resource at medpagetoday.com
Most Recently Shared on October 6, 2011 at 5:01 pm By:
Rejected weight-loss drug Contrave cuts heart risks #OBESITY2011: http://t.co/0yaqRQFA
FDA Panel Endorses Contrave Weight-Loss Drug - ABC News
abcnews.go.com — “An FDA advisory committee has voted 13-7 that the modest weight-loss benefits of an investigational combination of naltrexone and bupropion (Contrave) outweigh the drug's blood pressure risk.” View full resource at abcnews.go.com
Most Recently Shared on December 8, 2010 at 1:23 pm By:
Dr. Stephen Sinatra Nutritionist, Physician, Doctor, Internist, and Cardiologist
FDA panel recommends diet pill despite little benefit compared to placebo and real heart risks. Thumbs down! http://ow.ly/3lTsY
NDA submitted for Contrave for treatment of obesity - MPR
empr.com — “Orexigen announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of Contrave (naltrexone SR/bupropion SR) for the treatment of obesity.” View full resource at empr.com
Most Recently Shared on April 1, 2010 at 3:59 pm By:
MPR News: NDA submitted for Contrave for treatment of obesity: Orexigen announced that a New Drug Application (NDA... http://bit.ly/dqHz8n
FDA Panel Recommends Approval of New Obesity Medication
healthcentral.com — “FDA panel recommends approval of Contrave.” View full resource at healthcentral.com
Most Recently Shared on December 13, 2010 at 3:57 pm By:
FDA Panel Recommends Approval of New Obesity Medication http://sns.ly/NpG77
FDA accepts Orexigen's Contrave NDA for treatment of obesity
news-medical.net — “Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.” View full resource at news-medical.net
Most Recently Shared on June 2, 2010 at 10:46 am By:
Obesity News: FDA accepts Orexigen's Contrave NDA for treatment of obesity: Orexigen® Therapeutics, Inc., a biop... http://twurl.nl/kxptrd
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MNT Health News
Featured health news published by Medical News Today and chosen by the editorial team.
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
Sara Stein MD
Obesity Expert, Award-winning Author, SocMed, Universal Healthcare, Newfy lover, Mid-century Modern. Hope & Healing from Obesity one small change at a time!
Advertisement
